AC-262536

AC-262536 is a non-steroidal selective androgen receptor modulator developed by Acadia Pharmaceuticals — the same laboratory that produced ACP-105. It is an emerging research compound distinguished by its highly favorable anabolic-to-androgenic dissociation in preclinical models. AC-262536 demonstrated approximately 66% of testosterone's anabolic potency in skeletal muscle tissue while producing only 27% of testosterone's androgenic effect on the prostate — an anabolic-to-androgenic ratio of roughly 2.45:1 that significantly exceeds testosterone's 1:1 baseline and compares favorably to many established SARMs.

AC-262536 functions as a selective androgen receptor agonist, binding the AR with moderate affinity in muscle and bone tissue. Its selectivity mechanism parallels that of other non-steroidal SARMs: differential tissue-specific co-regulator recruitment results in robust anabolic transcriptional activity in skeletal muscle while limiting androgenic effects in reproductive organs. Preclinical research has also noted potential neuroprotective properties — AC-262536 has been investigated for its ability to reduce neuronal damage in Alzheimer's disease models, with early data suggesting AR-mediated neuroprotective signaling in hippocampal tissue.

While AC-262536 has a smaller research base than established SARMs like Ostarine or LGD-4033, the available preclinical data is consistently positive. Researchers report moderate lean mass accrual, improved muscular endurance, and, notably, a very low incidence of side effects — consistent with its favorable selectivity ratio. Its anabolic output is less aggressive than RAD-140 or LGD-4033, but its minimal androgenic footprint makes it an appealing option for conservative, long-duration research protocols.

AC-262536 is best suited for researchers who prioritize minimal systemic androgenic impact over maximum anabolic potency — beginners exploring SARMs for the first time, researchers running extended-duration protocols where cumulative side effects are a concern, or female researchers seeking low-virilization alternatives. It is also of interest to researchers investigating AR-mediated neuroprotection. For pure muscle-building objectives, more potent SARMs will deliver faster results; AC-262536's value lies in its exceptionally clean side-effect profile.

AC-262536 has an estimated elimination half-life in the range of 12–16 hours, generally supporting once-daily oral administration. Oral bioavailability is good. Testosterone suppression at standard research doses appears to be mild, consistent with its partial androgenic profile. PCT requirements are generally minimal for standard-dose, moderate-duration cycles, though a brief SERM course is advisable for cycles exceeding 8 weeks as a precaution. No hepatotoxicity data of concern has been reported. As an emerging compound, researchers should note that the pharmacokinetic profile is less precisely characterized than established SARMs. Typical research protocols range from 10–30mg daily for 8–12 weeks.

---

*Novo Pharma. Research-grade compounds. Third-party tested. Certificate of Analysis available for every batch.* # Novo Pharma — Peptide Product Detail Page Descriptions

All 45 peptide SKUs. Clinical, authoritative, premium voice. Research language throughout.

---

## Healing & Recovery